Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide Phase 1 in Japanese mCRPC
NCT02363855Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2015
- Primary completion
- Nov 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of darolutamide in metastatic castration-resistant prostate cancer (mCRPC) (2 cohorts), sponsored by Bayer. Primary endpoints: Treatment Emergent Adverse Events at 12 weeks, Intensity of Adverse Events at 12 weeks and 3 more. Started Feb 2015; status: completed.
02
Drugs
darolutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02363855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02363855.